Key transaction
Liquidia Corp (NASDAQ:LQDA) Chief Business Officer Jason Adair sold 7,301 shares of the company’s common stock on April 13, 2026, at a price of $38.37 per share, producing proceeds of $280,139. The disposition was made under a Rule 10b5-1 trading plan that Adair adopted on December 15, 2023.
Context on the stock
Liquidia’s shares have climbed 181% over the past 12 months and were trading at $38.71 at the time of the most recent report, translating to a market capitalization of $3.41 billion. According to InvestingPro analysis, the stock remains undervalued relative to its Fair Value, and the company has an upcoming earnings release scheduled for May 7. Investors seeking further detail are directed to the available Pro Research Report for LQDA, which includes 12 additional ProTips and deeper analysis.
Insider share conversions earlier in April
Earlier in the month, on April 10, 2026, Adair received shares through the conversion of equity awards. The conversions comprised 3,906 shares from restricted stock units, 2,474 shares from performance stock units, and an additional 3,868 shares through performance stock units.
Recent financials and product performance
Liquidia Technologies reported fourth-quarter 2025 results that reflected a mixed financial picture. Revenue outperformed expectations, fueled by the launch of Yutrepia, which generated $90.1 million in revenue and represented 74% quarter-over-quarter growth. Despite that top-line strength, earnings per share fell short of analyst projections.
Analyst reactions
Market analysts have adjusted their views following the company’s recent performance. H.C. Wainwright raised its price target for Liquidia to $55, citing robust earnings and movement toward profitability. BTIG increased its target to $50, pointing to the successful Yutrepia rollout. Raymond James kept a Strong Buy rating with a $47 target and compared Yutrepia’s early performance to Tyvaso DPI’s initial launch. BofA Securities reiterated a Buy rating with a $44 target, highlighting Liquidia’s positioning in the prostacyclin treatment space.
What remains to watch
With insider activity, notable quarterly revenue growth driven by a new drug launch, and upcoming earnings, investors have multiple near-term data points to monitor. The company’s valuation relative to its Fair Value is highlighted by InvestingPro, and the May 7 earnings release will provide further clarity on profitability trends.